Related Experiment Video
Updated: Sep 23, 2025

Electrocardiogram Recordings in Anesthetized Mice using Lead II
Published on: June 20, 2020
Aldehyde dehydrogenase 2 and arrhythmogenesis
Junyan Jin1, Jieying Chen1, Yaping Wang1
1Department of Cardiology, Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China.
Insights
Aldehyde dehydrogenase 2 (ALDH2) activation shows promise for treating cardiac arrhythmias, a major cardiovascular disease. Research highlights ALDH2
Area of Science:
- Cardiovascular Medicine
- Biochemistry
- Pharmacology
Background:
- Cardiac arrhythmia presents significant global health and economic challenges.
- Current antiarrhythmic therapies are suboptimal despite advancements.
- Aldehyde dehydrogenase 2 (ALDH2) is a key enzyme in detoxifying harmful aldehydes and mitigating oxidative stress.
Purpose of the Study:
- To review the role of ALDH2 activation in providing antiarrhythmic protection.
- To examine the impact of the ALDH2∗2 polymorphism (rs671) on arrhythmia risk.
- To discuss novel ALDH2 activators as potential antiarrhythmic agents.
Main Methods:
- Literature review of recent research on ALDH2 and cardiac arrhythmias.
- Analysis of studies investigating ALDH2 deficiency and arrhythmogenesis.
- Examination of findings on ALDH2 activators and their therapeutic potential.
Main Results:
- ALDH2 deficiency is linked to increased risk of cardiac arrhythmias.
- ALDH2 activation demonstrates potential benefits in preventing arrhythmias.
- The ALDH2∗2 polymorphism is associated with a higher susceptibility to arrhythmias.
Conclusions:
- ALDH2 activation offers a promising therapeutic strategy for cardiac arrhythmias.
- Targeting ALDH2 may lead to novel and effective antiarrhythmic treatments.
- Understanding ALDH2's role is crucial for managing cardiovascular disease risk.
Abstract:
Cardiac arrhythmia is a common cardiovascular disease that leads to considerable economic burdens and significant global public health challenges. Despite the remarkable progress made in recent decades, antiarrhythmic therapy remains suboptimal. Aldehyde dehydrogenase 2 (ALDH2), a critical detoxifying enzyme, catalyzes toxic aldehydes and protects individuals from damage caused by oxidative stress. Accumulating evidence has demonstrated that ALDH2 activation has potential antiarrhythmic benefits. The correlation between ALDH2 deficiency and arrhythmogenesis has been widely recognized. In this review, we summarize recent research on the potential role of ALDH2 activation and antiarrhythmic protection, as well as the role played by the ALDH2∗2 polymorphism (rs671) in promoting arrhythmic risk. Additionally, we discuss important new findings illustrating the use of ALDH2 activators, which may prove to be promising antiarrhythmic therapy agents.
Related Concept Videos
Mechanism of Cardiac Arrhythmias
Disturbances in Heart Rhythm
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Electrophysiology of Normal Cardiac Rhythm
Dysrhythmias II: Classification of Tachyarrhythmias

